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Introduction
Immunotherapy with immune checkpoint inhibitors (ICIs) has radically improved survival across a range of  
cancers in the last decade (1). ICIs are antibodies blocking the interaction between negative costimulatory 
receptors present on the cell surface of  certain immune cells, such as cytotoxic T lymphocytes (CD8+ T 
cells), and their ligands (2). Several cancers actively suppress these receptors to silence or exhaust surround-
ing immune cells, thereby evading immune surveillance and subsequent cytolysis. Blocking this interaction 
serves as a way to keep T cells active, allowing a sustained destruction of  cancer cells by the immune sys-
tem. ICIs targeting the programmed cell death 1 protein (PD-1) and programmed death ligand 1 (PD-L1), 
alone or in combination with the cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), are now used as 
first-line therapy for late-stage cancers, including metastatic melanoma (MM), non–small cell lung cancer 
(NSCLC), and renal cell carcinoma (RCC). In fact, 5-year overall survival rates for patients with MM soared 
from 16% to 52% after the introduction of  an anti–CTLA-4 + anti–PD-1 combination therapy (3, 4).
Nonetheless, half  the patients do not respond to ICI therapy, and predictions of  which patients belong 
to the responder (R) or nonresponder (NR) phenotype are not yet possible. Previous studies examining 
the intrinsic oncogenic features of  the tumor have revealed several processes that negatively correlate with 
BACKGROUND. Identifying factors conferring responses to therapy in cancer is critical to select the 
best treatment for patients. For immune checkpoint inhibition (ICI) therapy, mounting evidence 
suggests that the gut microbiome can determine patient treatment outcomes. However, the 
extent to which gut microbial features are applicable across different patient cohorts has not been 
extensively explored.
METHODS. We performed a meta-analysis of 4 published shotgun metagenomic studies (Ntot = 
130 patients) investigating differential microbiome composition and imputed metabolic function 
between responders and nonresponders to ICI.
RESULTS. Our analysis identified both known microbial features enriched in responders, such as 
Faecalibacterium as the prevailing taxa, as well as additional features, including overrepresentation 
of Barnesiella intestinihominis and the components of vitamin B metabolism. A classifier designed 
to predict responders based on these features identified responders in an independent cohort of 27 
patients with the area under the receiver operating characteristic curve of 0.625 (95% CI: 0.348–
0.899) and was predictive of prognosis (HR = 0.35, P = 0.081).
CONCLUSION. These results suggest the existence of a fecal microbiome signature inherent across 
responders that may be exploited for diagnostic or therapeutic purposes.
FUNDING. This work was funded by the Knut and Alice Wallenberg Foundation, BioGaia AB, and 
Cancerfonden.
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treatment response; see ref. 5 for a comprehensive review on the topic. These include low mutational bur-
den (6), presence of  mutations in the interferon-γ (IFN-γ) signaling pathway (7), downregulation of  the 
human leukocyte antigen genes (8), and the presence of  a transcriptional signature characterized in part by 
overexpression of  cyclin-dependent kinase activity (9).
ICI therapy does not target the cancer cells directly but rather their interplay with immune cells. There-
fore, it is important to consider the role of  whole-body immunity in each patient. Whole-body immunity 
is affected through several host and lifestyle factors, such as age, diet, and environment. It has recently 
emerged that the complex interplay between lifestyle and host immunity is in part mediated by the compo-
sition of  the gut microbiota. Microorganisms in our gut are continually interacting with the gut epithelial 
barrier, through direct interactions with the microorganisms themselves, or through the myriad of  diverse 
compounds they produce when metabolizing our diet (10, 11). Immune cells lining the gut mucosa have 
the privileged position to sense and be affected by changes in microbial ecology, subsequently triggering the 
activity of  near and distal T cells, which can ultimately affect ICI outcomes (12). Previous studies in mice 
revealed that germ-free or antibiotic-treated mice were unable to respond to ICI therapy (13, 14). Treatment 
outcomes for sarcoma and melanoma mouse models could then be restored by introducing specific bac-
terial taxa from the Bacteroides and Bifidobacterium phyla, respectively (13, 14). The establishment of  a 
causal relationship between specific taxa and their ability to significantly affect ICI outcomes has also been 
extended to humans. However, the exact mechanisms and requirements remain unclear. Because the gut 
microbiome composition varies tremendously across people, it remains difficult to know how well one can 
extend these findings across different regional boundaries. In fact, each study reports a unique set of  micro-
bial patterns predictive of  response to ICI therapy. This issue could potentially hamper the development 
and applicability of  pre- and probiotics for boosting ICI outcomes across the population.
In this study, we collected the published whole metagenome shotgun sequencing (MGS) gut microbi-
ome data sets obtained from patients with MM undergoing anti–PD-1, –PD-L1, –CTLA-4, or combination 
immunotherapy (15–18) and performed a meta-analysis on the compositional and functional features of  
the microbiota between R versus NR across studies.
Results
Study selection and characteristics. After a manual search from literature databases, we included any studies 
investigating the gut microbiome effects of  cancer ICI therapy with publicly available fecal MGS data and 
associated metadata (Table 1, Methods). We excluded nonfecal samples from each data set, along with 
any samples taken during treatment. In order to categorize each patient as belonging to either a responder 
or nonresponder phenotype, we sourced the available metadata in each study. Treatment responses were 
evaluated through the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as determined in 
the original study at first response evaluation (19). Patients with complete or partial response, according 
to RECIST 1.1 criteria, were classified as responders, whereas patients with stable or progressive disease 
were classified as nonresponders. We initially included a study investigating links between microbiome 
composition and response to immunotherapy in RCC and NSCLC patients (20). However, we failed to 
identify any remarkable shifts in microbiome composition according to our predefined response criteria, 
both in the study itself  and when pooling the data across studies (Supplemental Figures 1–4 and Sup-
plemental Figure 6; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.140940DS1). For consistency, we decided to limit our scope to the MM subgroup of  patients. This 
was further motivated by the fact that the Peters et al. data set (18), which we used for validation, consists 
exclusively of  patients with MM. In total, the final set of  exclusively MM patients used throughout this 
analysis included 66 responders and 64 nonresponders.
Compositional differences of  the microbiome between responders and nonresponders. All the raw sequencing 
data and metadata for each study were consistently reprocessed and reanalyzed according to a self- 
developed bioinformatics pipeline as described in the Methods section (Figure 1). Examining taxonom-
ic distribution at the family and genus level did not reveal remarkable differences between NR and R 
groups (Supplemental Figure 1). When grouped by study, we identified larger relative abundances of  
taxa belonging to the Lachnospiraceae and Ruminococcaceae families in the Frankel et al. data set. At 
the genus level, the Frankel et al. data set tended to contain increased relative abundances of  the Blautia 
genus compared with the remaining studies. Comparisons of  alpha-diversity, a measure of  microbial 
community diversity within each patient, at the species level between response groups for the pooled 
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data did not result in significant differences (P > 0.05, Wilcoxon’s rank-sum test) according to multiple 
alpha-diversity indices. The lack of  significant differences in diversity between R and NR hints that a few 
individual microbes might drive phenotypic differences in these patients.
We next performed beta-diversity analysis, which measures microbial community diversity between 
patients, based on taxonomic composition at the species level using multidimensional scaling (MDS) with 
weighted UniFrac distances, to see if  we could cluster patients in R and NR separately. For each individual 
study, we only observed a marked difference in beta-diversity between the R and NR groups in the Gopal-
akrishnan et al. data set (15) (Figure 2A). Pooling the data and running MDS did not produce any apparent 
difference in beta-diversity between R and NR patients; in fact samples from individual studies tended 
instead to cluster together (Figure 2B).
Given that no consistent difference between R and NR could be observed at the global level, we inves-
tigated to extract differentially abundant species between R and NR using several methods (Methods, Sup-
plemental Figure 4). Differential abundance testing between R and NR for the melanoma subset yielded 
17 differentially abundant species (P < 0.05, unadjusted, Wilcoxon’s rank-sum test, Supplemental Table 
1). Hierarchical clustering of  patients using only the differentially abundant species revealed 2 clusters, one 
enriched in R and the other enriched with NR (Figure 2C, P = 0.0013, Fisher’s exact test). Among the most 
abundant species, we observed that R patients were enriched in unknown Ruminococcaceae species, unknown 
Faecalibacterium species, Ruminococcus bicirculans, and Barnesiella intestinihominis, whereas NR patients were 
enriched in Bacteroides thetaiotaomicron, Adlercreutzia equolifaciens, Bifidobacterium dentium, and unknown Mogi-
bacterium. Notably, we did not observe any major clustering of  samples by study of  origin using the differ-
entially abundant species. To check the validity of  our approach, we reanalyzed differentially abundant 
taxa between R and NR on a per-study basis (Supplemental Figure 3). Consistent with our pooled findings, 
we replicated the majority of  the findings in each individual study (some taxa identified to be differentially 
Table 1. Summary of the studies used for the meta-analysis
Study Year ICI therapyA Sequencer NB R NR Reference
Gopalakrishnan et al. 2018 Anti–PD-1 Illumina HiSeq 2000 25 14 11 15
Matson et al. 2018 Anti–PD-1 Illumina NextSeq 500 39 15 24 16
Frankel et al. 2017 Anti–PD-1, Anti–CTLA-4, 
Anti–PD-1 + Anti–CTLA-4
Illumina HiSeq 2000 39 19 20 17
Peters et al. 2019 Anti–PD-1, Anti–CTLA-4, 
Anti–PD-1 + Anti–CTLA-4
Illumina HiSeq 2500 27 16C 11C 18
The meta-analysis included 130 patients, consisting of 66 responders and 64 nonresponders. AAntibodies used: Anti–PD-1: nivolumab or pembrolizumab; 
Anti–CTLA-4: ipilimumab. BThe total number is based on which patients had MGS data available at baseline. CThe responders (R) and nonresponders (NR) 
were classified based on progression-free survival (PFS); R, PFS ≥ 6 months; NR, PFS < 6 months.
Figure 1. Meta-analysis workflow. In brief, fecal MGS data at baseline from 4 studies (N = 130) comparing differences in microbiome composition between 
R and NR were systematically reanalyzed at the taxonomic, genetic, and functional level. We set aside data from one of the studies (18) (N = 27) in order 
to validate our findings in an independent cohort. WGS, whole-genome sequencing.
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Figure 2. Differences in microbial abundances between responders and nonresponders to ICI therapy. (A) Multidimensional scaling (MDS) analysis using 
weighted UniFrac distances of samples (N = 103) pertaining to each study and grouped by response. (B) MDS plot of all samples included in the meta-anal-
ysis, grouped by response. Dashed and solid lines indicate 95% normal confidence ellipses for each study and response group, respectively. (C) Hierarchical 
clustering of log-normalized abundances of differentially abundant taxa between R and NR for only the melanoma subset of patients. Seventeen opera-
tional taxonomic unit (OTUs) were identified as differentially abundant with P < 0.05 (Wilcoxon’s rank-sum test).
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abundant in the original study but not in the present meta-analysis all had unadjusted P values slightly higher 
than 0.05). This indicates that the gut microbiome is heterogenous between patient populations, but there 
seems to exist a common species repertoire across the majority of  patients.
In order to identify whether there were any differences in the topology of  the microbial association 
network between the R and NR groups, as well as to map out microbes serving as network hubs, we per-
formed a co-occurrence analysis at the genus level on the pooled data (Supplemental Figure 5). Highly 
interconnected microbes in the co-occurrence networks can serve as regulators for the general community 
structure and might be useful for targeted therapeutics, to alter the microbiome structure from an NR to R 
phenotype. We observed similar network interconnectivity in R versus NR. However, whereas Mogibacte-
rium, Anaerococcus, and Eggerthella formed the largest hubs in the R network, in NR, the largest hubs were 
dominated by Subdoligranulum, Lachnoclostridium, Eggerthella, and Streptococcus. While Mogibacterium was 
identified as being increasingly abundant in NR, the fact that it co-occurs with several bacterial species in 
the R network suggests that it might have an interesting role for maintaining an R microbiome structure. 
Nonetheless, it is important to note that co-occurrence does not directly imply any causal dependence 
between microbes, e.g., metabolite exchange as a form of  symbiosis.
Functional differences of  the microbiome between responders and nonresponders. In order to understand the 
functional consequences of  differential abundance of  specific species in R versus NR, we next focused on 
genes associated with metabolic pathways. We initially examined the genetic content on a gene-by-gene 
basis; however, we did not find anything remarkable. To enhance interpretability of  the findings, we exam-
ined genes mapped onto MetaCyc pathways, which resulted in approximately 500 features. Dimensionality 
reduction analysis of  the functional content between R and NR showed minimal separation between each 
of  the groups when pooling all the studies (Supplemental Figure 6). Differential abundance tests of  each 
MetaCyc pathway — defined as the lowest number of  reads mapping to individual pathway-associated 
genes — between R and NR resulted in 29 differentially abundant pathways (Supplemental Table 1, P < 
0.05, unadjusted, Wilcoxon’s rank-sum test). Hierarchical clustering of  patients using these 29 pathways 
resulted in the emergence of  2 large clusters enriched either in R or in NR (Figure 3, P < 0.0001, Fisher’s 
exact test). The majority of  these differentially abundant pathways were enriched in R, covering a wide 
array of  biological processes, including starch and glycoside degradation, thiamine metabolism, cobalamin 
metabolism, peptidoglycan maturation, and nucleotide degradation. The differentially abundant pathways 
enriched in NR covered a narrower span of  processes, specifically nucleotide biosynthesis and aerobic res-
piration, although the latter was represented in low copies across samples. We were interested in manually 
examining the reads mapping onto the aerobic respiration pathway in order to identify potential pathogens. 
Although a large part remained unmapped, the annotated reads were found to be belonging to Campylo-
bacter and Citrobacter genera, both of  which are members of  the Proteobacteria phylum.
Reanalyzing the functional content of each study individually, we again managed to replicate many of the 
original findings in the original studies (Supplemental Figure 7). These included upregulation of inositol metab-
olism in R, reported by Frankel et al. (17), and degradation pathways enriched in R and biosynthesis pathways 
enriched in NR, reported by Gopalakrishnan et al. (15). Matson et al. did not report any functional analysis of  
their MGS data (16), but we managed to observe increased nucleotide biosynthesis in NR and increased biosyn-
thesis of more complex organic compounds, such as isoprenoids, polyamines, and coenzymes, in R.
Translating microbiome signatures predictive of  response to ICI across studies. These results suggest that taxo-
nomic as well as functional microbial features define a complex signature associated with response to ICI in 
MM. However, our findings also highlighted substantial heterogeneity across the studies questioning whether 
these features are actually predictive of  response to ICI or are a spurious finding resulting from reducing the 
initial dimensionality until a separation between the groups was achieved. Therefore, we decided to vali-
date this signature in an independent cohort. Specifically, we tested whether the feature set was predictive 
of  response in the study by Peters et al. (18). We tackled this through a machine learning–based approach, 
where we used our differentially abundant species and pathways as selected feature inputs for a random forest 
(RF) classifier (Figure 4A). After training the RF classifier, we examined the most important features in the 
classification, evaluated by mean decrease in Gini impurity (Figure 4B). The most predictive feature overall 
was the abundance of  an unknown Faecalibacterium, with the second most being the abundance of  aerobic 
respiration (PWY-3781). Classification performance of  the model on the training data was evaluated based 
on the receiver operating characteristic curve (ROC), reaching an area under the ROC curve (AUC) of  0.604 
(95% CI: 0.511–0.709), indicating a modest yet nonrandom separation between R and NR (Figure 4C, left). 
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Because Peters et al. did not classify patients into R versus NR explicitly (18), we categorized each patient as 
belonging to R or NR based on PFS less than or greater than 6 months, respectively, consistent with the other 
studies. The prespecified RF classifier achieved a classification performance on the test data consistent with 
the training sets (Figure 4C, right, AUC = 0.624, 95% CI: 0.348–0.899). When we performed unsupervised 
hierarchical clustering based on the features used in the RF classifiers to examine patients in the validation 
data, we observed a separation between the R and NR classes (Supplemental Figure 8). This is strongly sug-
gestive that the here-reported signature incorporating taxonomic and functional features of  the gut microbi-
ome represents a modest yet predictive factor of  response to ICI in MM.
Next, we investigated whether grouping of  patients into R versus NR according to the RF classifier was 
prognostic in the validation data in terms of  PFS. Considering the fact that only 27 baseline samples were 
present in the validation data set (N = 16 responders), we sought to determine the statistical power of  a log-
rank test by performing an a priori minimum detectable effect (MDE) calculation and so quantify the required 
hazard ratio between the R and NR groups at a 5% significance level. The MDE for the hazard ratio was 
0.17 (Methods). We observed that categorization of  patients into R according to the RF classifier resulted 
in a hazard ratio of  0.35 for PFS, as shown in Figure 4D, bottom. Kaplan-Meier survival estimates man-
aged to separate both classes, albeit not enough to reach significance (P = 0.081, log-rank test, Figure 4D). 
Figure 3. Alterations in the functional potential of the gut microbiome between responders and nonresponders to ICI therapy. Log-normalized 
abundances reported as copies per million (CoPM, analogous to TPM for RNA-Seq data) of differentially abundant MetaCyc pathways present in the fecal 
microbiome of patients (N = 103). Twenty-nine pathways were identified as differentially abundant with P < 0.05 (unadjusted, Wilcoxon’s rank-sum 
test). PWY-tags preceding each pathway name are unique IDs associated with each metabolic pathway on MetaCyc. Hierarchical clustering dendrogram 
for the pathways is omitted due to figure size constraints.
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This was expected given we previously determined that the log-rank test was underpowered to detect signif-
icance at 5% confidence level for hazard ratio estimates greater than 0.16. This finding extends the previous 
result and suggests that the here-reported signature is also quantitatively correlated to the duration of  response 
to ICI in an independent cohort of  patients with MM.
Discussion
In this meta-analysis, we aimed to understand which features of  the microbiome consistently correlate with 
response to ICI across studies in patients with MM. In addition, we investigated several additional features 
as well as mapped out their likely biological role in mediating the clinical benefits. Global microbiome struc-
ture does not seem to cluster based on response phenotype alone, as evident by the poor separation between 
classes in the MDS plots. This could owe to other factors that correlate with microbial composition in a more 
Figure 4. Microbial signatures in patients with melanoma are predictive of PFS in an independent cohort. (A) Construction of a random forest (RF) clas-
sifier for treatment response to ICI, based on fecal sequencing data. Differentially abundant features (kpool = 49) between R and NR patients (N = 103) were 
selected as input for training an RF classifier. The trained model was then used to predict treatment responses of patients in an independent cohort (N = 
27). (B) Lollipop plot of the top 10 most important variables, evaluated according to the mean decrease in Gini impurity as determined by the RF classifier 
after model training. Features are color-coded according to species or pathway. (C) Performance characteristics of the RF classifier. Left: Receiver operating 
characteristic (ROC) curves on the training and test data. AUC, area under the curve. Right: Confusion matrices and prediction scores for the RF classifier 
on the training and test data. (D) Kaplan-Meier PFS estimates for the R and NR patients, as predicted by the RF classifier (P value using the log-rank test), 
with number of patients at risk for each 5-month interval and hazard ratio for the R group (calculated using Cox proportional hazards regression).
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direct way, such as genetics, diet, geographical location, and choice of  protocols for bacterial lysis and DNA 
extraction. It is worth noting that the lack of  global separation may also be due to inherent biases caused by 
the experimental design, including patient preselection. For example, patient microbiomes might be initially 
characterized using 16S rRNA gene sequencing (16S-Seq), and then a subset of  these with interesting microbi-
al patterns may then be further analyzed in detail using whole-genome sequencing, which is more costly. The 
advantage of  a meta-analysis is to identify factors independent of  biases introduced by specific choices in the 
experimental design of  a given study and are therefore more likely to be inherent to response and whole-body 
immunity. We also did not observe higher microbial community diversity in the responder group. In fact, the 
importance of  community diversity in ICI outcomes remains to be determined. Although higher community 
diversity has generally been associated with a microbiome belonging to a healthy state across multiple diseases 
(21–23), only the Gopalakrishnan et al. study (15), as well as the 16S-Seq data from the Peters et al. study (18), 
have reported higher diversity in responders to ICI. A previous meta-analysis of  microbial data sets found 
that reduced alpha-diversity is only characteristic of  very few diseases (24), and our study agrees that this is 
also the case in MM patients’ response to ICI. When analyzing community structure through co-occurrence 
networks, we found several genera serving as network hubs. However, the implications of  these in cancer or 
immunity has yet to be determined, with the exception of  Lachnoclostridium, which has recently been found 
to be a marker for the progression of  colorectal cancer (25). Targeting the large hubs in the nonresponder 
network might serve as a way to alter the microbiome composition in these patients, although it is important 
to note that co-occurrence of  2 microbes does not imply that the microbes share any dependencies for growth.
At the microbial composition level, we reidentified several beneficial taxa that had been previously 
described as enriched in responders of ICI in melanoma. We stress that the methods chosen for significance 
testing are not statistically rigorous due to no adjustment for multiple testing being used; instead we used them 
simply to extract features that differed between R and NR. The differentially abundant taxa in R included 
species in the Faecalibacterium genus and Ruminococcaceae family, both of which were associated with R in 
several of the studies included in this analysis. Interestingly, by pooling data and increasing statistical power, we 
discovered additional taxa in the context of response to ICI. This includes Barnesiella intestinihominis, which has 
been shown to control the efficacy of the immunomodulatory chemotherapeutic cyclophosphamide in mice by 
inducing IFN-γ production by γδ T cells at the site of the tumor (26). It can therefore be conjectured that this 
mechanism could be conserved in humans also. We also identified Ruminococcus bicirculans as being enriched 
in R. Ruminococcus bicirculans was shown to harbor a specialized ability to degrade certain plant hemicelluloses 
(27). This is an important property for shaping and maintaining a functional microbiome composition through, 
for instance, supplying molecular hydrogen to neighboring Archaea (28). Surprisingly, Bacteroides thetaiotao-
micron was found to be enriched in the NR group among the pooled MM patients, contrary to the findings 
of Peters et al., where it was enriched in R (18). This might be due to study-specific differences in microbi-
ome composition, and further studies are needed to understand the effect of Bacteroides thetaiotaomicron on ICI 
response. Bacteroides thetaiotaomicron has recently been identified as having cancer-preventative activities, by 
metabolizing compounds found in cruciferous vegetables into chemopreventative isothiocyanates (29). Addi-
tionally, we identified the taxon Adlercreutzia equolifaciens as being enriched in NR in our training data, whereas 
it was enriched in R in the Peters et al. data set (Supplemental Figure 8). Adlercreutzia equolifaciens is a producer 
of equol (30), a polyphenolic compound able to bind to the human estrogen receptor–β, although how and 
whether this potentially relates to negative stimulation of immunity remain to be understood.
At the functional level, several of  the processes enriched in R were centered on B vitamin metabolism, 
more specifically that of  thiamine (vitamin B1) and cobalamin (vitamin B12). Data from the Peters et al. study 
had indicated the riboflavin (vitamin B2), pantothenate (vitamin B5), pyroxidal 5-phosphate (vitamin B6), and 
folate (vitamin B9) biosynthesis pathways as being predominantly present in NR (18), whereas a prior study 
investigating links between the gut microbiota and incidences of  ICI-induced colitis events identified ribo-
flavin, pantothenate, and thiamine as enriched in patients with low risk for developing colitis (31). Specific 
studies examining direct links between B vitamin supplementation and immune system modulation have also 
been conducted (32–34). These include a randomized controlled trial examining vitamin supplementation in 
patients with HIV, of  which vitamin B2 and B12 were among the included vitamins. The vitamin-supplement-
ed group had significantly higher CD8+ and CD4+ T cell counts, as well as lower disease progression (34). 
Because we identified 3 independent thiamine metabolic pathways, we hypothesize that supplementation 
of  either the metabolite itself, or thiamine-producing bacteria, might be an interesting avenue to explore as 
an adjuvant in conjunction with current ICI regimens. However, the exact role of  microbially produced B 
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vitamins in the context of  ICI will have to be further evaluated in future studies, as well as whether these 
findings represent a causal process for increased immune system stimulation. We also found several catabolic 
pathways, e.g., starch, glycoside, and nucleotides, enriched in R. These could potentially indicate features of  a 
healthy microbiota, whereby microbial catabolism of these compounds allows the host to absorb and utilize 
microbially derived products. This stands in contrast with the aerobic respiration and nucleotide biosynthesis 
pathways enriched in NR, which are features of  noncommensality and increased growth, respectively. We 
confirmed this by identifying that aerobic respiration seems to in part be driven by the Campylobacter and 
Citrobacter genera, both of  which are opportunistic pathogens. In summary, analysis of  the functional con-
tent of  the gut microbiota is suggestive that vitamin B metabolism may be mechanistically implicated in ICI 
response, whereas a healthy microbiota could be a prerequisite for response.
The differentially abundant microbial features constituted a signature of  response to ICI in MM. We 
constructed an RF classifier based on this signature in order to examine whether we could predict patient 
response. We found that Faecalibacterium was significantly more abundant in R (mean log2 fold change of  
2.54) as well as being the most important predictor in the classifier, which further validates its importance 
in ICI treatment outcomes. Notably, 7 out of  the 10 most important features consisted of  functional path-
ways, which could imply that function might be a more generalizable feature of  response compared with 
individual microbes. The fact that microbiome-associated changes correlated with response in an indepen-
dent cohort is strongly suggestive that this signature could be generalized and underscores its contribution 
to the response to ICI in MM. However, the performance of  the model needs to be increased before micro-
biome associated changes can be used as a predictor for response to ICI across distinct patient populations. 
Performance could potentially be increased by including additional layers of  omics data, such as metatran-
scriptomics or metaproteomics, allowing for a more functional snapshot of  the biological processes that are 
being actively expressed compared with MGS. Furthermore, it would be of  interest to generate predictive 
models that incorporate additional clinical parameters (age, sex, body mass index, serum lactate dehydro-
genase levels), data from patient tumors (whole-genome sequencing, chromatin accessibility assays, RNA-
Seq), and immune system state (immune profiling panels, TCR-Seq), along with fecal metagenomics data.
In conclusion, this meta-analysis provides several microbial features predictive of  response that are gen-
eralizable across studies. These features will have to be experimentally validated in future studies to verify 
their therapeutic or predictive potential.
Methods
Literature review. We began by performing a literature search on PubMed/MeSH for any published articles 
relating to immunotherapy and the gut microbiome in humans using the following query (performed in 
February 2019): “(((((“journal article”[Publication Type]) AND (“immunotherapy”[MeSH Major Topic])) AND 
(“microbiota”[MeSH Terms])) AND (humans[MeSH Terms])) NOT (“review”[Publication Type]))”
This resulted in 38 records, which we screened and excluded all studies that did not contain human 
fecal MGS data from melanoma patients undergoing checkpoint immunotherapy. In total, we obtained 3 
eligible studies from PubMed, Gopalakrishnan et al. (15), Matson et al. (16), and Routy et al. (20). Addi-
tionally, we identified the Frankel et al. study from the references of  a perspective piece by Gopalakrishnan 
et al. (35). We repeated the search on PubMed in December 2019 using the same query, which allowed us 
to identify and include another eligible study by Peters et al. (18). Finally, after initial analysis (Supplemen-
tal Figure 1–4, Supplemental Figure 6), we restricted the scope of  our studies to melanoma patients, there-
by discarding the Routy et al. data set, which only included RCC and NSCLC patients. To our knowledge, 
no other studies relating checkpoint immunotherapy outcomes to fecal MGS data have been performed 
since the Peters et al. study. No protocol exists for the literature review.
Data set and metadata collection. MGS data from each study were obtained from the European Nucle-
otide Archive under the accession numbers PRJEB22893, PRJNA399742 (15), PRJNA397906 (15), 
PRJEB22863 (15), and PRJNA541981 (15). We excluded any samples taken after commencing ICI ther-
apy, non-MGS samples, and nonfecal samples. Patient metadata from each study were obtained through 
the main manuscript for the Frankel et al. data; the study GitHub repository (https://github.com/crib-
ioinfo/sci2017_analysis) for the Matson et al. data; NCBI BioProject (https://www.ncbi.nlm.nih.gov/
bioproject) with accession ID PRJEB22863 for the Routy et al. data; and European Genome-phenome 
Archive with accession ID EGAS00001002698 and access granted from the study authors for the Gopal-
akrishnan et al. data set. All scripts, files, and data used for the analysis are publicly available on GitHub at 
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https://github.com/angelolimeta/Gut-microbiome-immunotherapy. Processing steps utilizing command 
line tools were performed in a reproducible Conda environment (Anaconda, Version 2-2.4.0, https://
www.anaconda.com) with the Snakemake workflow engine (36) on a computational cluster.
Patient stratification. In order to avoid bias from differing assignments of  treatment response criteria, 
we consistently classified patients into responder and nonresponder groups through the RECIST 1.1 (19). 
Patients with complete or partial response, according to RECIST 1.1 criteria at first evaluation, were clas-
sified as responders, whereas patients with stable or progressive disease were classified as nonresponders.
Summary measures. The principal summary measures used throughout the analysis were log-normalized 
relative abundances of  microbes and pathways in each sample.
Microbial composition analysis. Raw FASTQ reads were quality filtered using fastp (37) with default 
parameters. In order to profile the microbial composition in each sample, we opted for a phylogenetic 
marker gene alignment–based approach using mOTUs2 (38) with default parameters. The resulting output 
from mOTUs2 after merging all samples is a tab-separated file containing, for each sample, counts for the 
number of  reads that could be mapped to a given phylogenetic marker gene. Each marker gene is a sin-
gle-copy gene acting as a marker for a given operational taxonomic unit (OTU), i.e., a microbe profiled at 
a specific phylogenetic resolution. For downstream analyses we also downloaded the phylogenetic tree file 
for all the OTUs included in mOTUs2. The tab-separated output file from mOTUs, phylogenetic tree file, 
and sample metadata were loaded into R and packaged into a phyloseq (39) object for ease of  analysis. In 
order to adjust for sequencing depth across samples, raw counts for each OTU were converted into relative 
abundance values by dividing by the total amount of  counts for each sample. For dimensionality reduction 
and visualization purposes, the relative abundances were also log-normalized. A small value of  10–8 was 
added to the relative abundances prior to normalization to avoid taking the logarithm of  0. Microbes not 
present in at least 5 samples were discarded from the normalized data set.
Global differences in microbial composition between patients were visualized using weighted UniFrac 
distance-based dimensionality reduction techniques, through incorporation of the phylogenetic tree data from 
mOTUs2. UniFrac variants of the MDS and t-distributed stochastic neighbor embedding (https://github.
com/opisthokonta/tsnemicrobiota) algorithms were both used. Phylogenetic alpha-diversity indexes (Shan-
non, Inverted Simpson, ACE, and Chao1) were calculated for each sample, based on the identified OTUs. 
Differences in alpha-diversity between R and NR were assessed by applying 2-sided Wilcoxon’s rank-sum tests. 
Differentially abundant/present microbes between R and NR were extracted using 2 different methods. First, 
we performed 2-sided Wilcoxon’s rank-sum tests between R and NR on the log-normalized CoPM abundance 
for each microbe and considered any microbe with a P value (unadjusted for multiple testing) of less than 0.05 
to be differentially abundant. Second, we ran through the raw microbial count data through the DESeq2 tool 
(40) and included treatment response (R and NR), antibody type (anti–PD-1, anti-CTLA-4, and combination 
therapy), and source study in the design matrix. Size factor estimation in DESeq2 was performed using the 
poscounts method. P values between R and NR obtained for each microbe were adjusted using the Benjami-
ni-Hochberg procedure into q values, and all microbes with a q < 0.05 were considered differentially abundant.
Co-occurrence network analysis. Evaluating which microbes co-occur, i.e., their abundances are positively 
correlated, across a certain group of  patients, e.g., R and NR, can yield insights into the network struc-
ture of  the microbiome and uncover functional relationships between individual microbes. We performed 
co-occurrence analysis using the microbiomeSeq R package, for both the R and NR patient subsets. We 
defined pairs of  microbes as co-occurring across samples if  their Pearson’s correlation coefficient was above 
0.3. P values obtained from pairwise correlations were adjusted using the Benjamini-Hochberg procedure.
Functional profiling of  the microbiome. In order to profile the functional content, i.e., abundance of different 
pathways and genes/proteins, of the microbiota between samples, we used the HMP Unified Metabolic Anal-
ysis Network 2 (HUMAnN2) tool (41). HUMAnN2 was used in conjunction with the following databases: 
CHOCOPhlAn version 20, used for intermediate microbial profiling; UniRef50 gene clusters, used for quantify-
ing genes/proteins; and MetaCyc in conjunction with the UniRef50 gene clusters, used for quantifying pathway 
abundances and coverages. In order to visualize global differences in the functional profile for each patient, we 
first utilized standard principal components analysis. In addition to this, we applied the manifold learning tech-
nique uniform manifold approximation and projection (UMAP) (42) on the data sets in order to capture non-
linear patterns in the data. UMAP was performed using the umap R package with default parameters (https://
github.com/tkonopka/umap). Differential abundance tests between R and NR were performed using the 2-sided 
Wilcoxon’s rank-sum test, and all pathways with an unadjusted P < 0.05 were considered differentially abundant.
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Machine learning. Differentially abundant microbes and pathways were pooled together and used to 
train an RF classifier with 100,000 trees (43). The RF classifier was exclusively trained on data from the 
melanoma studies, then used to predict response labels on fecal whole-genome sequencing data obtained 
from patients in the validation data set. Model performance on the training and testing data was evaluated 
using ROC curves, as well as contingency matrix metrics. Individual features in the trained classifier were 
ranked according to importance using the mean decrease in GINI metric.
Since the validation data set contained a limited number of  participants (N = 27), we decided to per-
form an a priori MDE analysis to gauge how well our model needs to perform to achieve statistical sig-
nificance. Our RF classifier classified each patient in this data set as belonging to R or NR, and we then 
performed a log-rank test comparing each patient group based on PFS. The MDE analysis tells us the 
minimum hazard ratio required to achieve significant differences in PFS (P > 0.05) for a given power level. 
We utilized the Freedman method (44) for calculating the critical hazard ratio:
  (Equation 1),
where ln(θ) is the log-hazard ratio, z is the probit function, α is the type I error, β is the type II error, n is 
the total number of  patients, pR is the proportion of  true responders (PFS > 6 months), and pE is the overall 
probability of  progression occurring within the study period. From our data we obtained n = 27, pR = 0.66, 
pE = 0.44. Setting a type I error level of  0.05 and a type II error level of  0.2 yielded a critical log-hazard ratio 
of  –1.79, resulting in a hazard ratio of  0.166.
Availability of  code. All scripts used for the processing and analysis of  data are available at https://
github.com/angelolimeta/Gut-microbiome-immunotherapy.
Statistics. Analyses of  processed metagenomics data were conducted in the R software package (version 
3.6.1 “Action of  the Toes”; The R Project for Statistical Computing, http://www.R-project.org). Two-
tailed P values less than 0.05 were considered statistically significant across all tests. Statistical compari-
sons of  log-normalized microbial and pathway abundances, and microbial alpha-diversity indexes between 
groups, were performed using the 2-sided Wilcoxon’s rank-sum test. Fisher’s exact test was utilized for 
clustering comparisons of  patients using differentially abundant features. When analyzing differences in 
survival between predicted patient groups, we utilized the log-rank test.
Study approval. Study approval was not required as all the patient data used in this study are ano-
nymized and already exist in the public domain.
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